Amicus Therapeutics, Inc. (DELISTED) (FOLD:DL)
14.49
0.00 (0.00%)
USD |
NASDAQ |
May 07, 16:00
Amicus Therapeutics Gross Profit Margin (Quarterly) : 84.64% for Dec. 31, 2025
Gross Profit Margin (Quarterly) Chart
Historical Gross Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2025 | 84.64% |
| September 30, 2025 | 87.38% |
| June 30, 2025 | 88.97% |
| March 31, 2025 | 89.19% |
| December 31, 2024 | 88.73% |
| September 30, 2024 | 89.08% |
| June 30, 2024 | 89.39% |
| March 31, 2024 | 85.76% |
| December 31, 2023 | 88.26% |
| September 30, 2023 | 88.24% |
| June 30, 2023 | 88.02% |
| March 31, 2023 | 90.50% |
| December 31, 2022 | 87.86% |
| September 30, 2022 | 81.98% |
| June 30, 2022 | 88.19% |
| March 31, 2022 | 88.58% |
| December 31, 2021 | 88.60% |
| September 30, 2021 | 83.39% |
| June 30, 2021 | 87.15% |
| March 31, 2021 | 87.74% |
| December 31, 2020 | 83.05% |
| September 30, 2020 | 83.84% |
| June 30, 2020 | 86.02% |
| March 31, 2020 | 86.26% |
| December 31, 2019 | 84.70% |
| Date | Value |
|---|---|
| September 30, 2019 | 86.24% |
| June 30, 2019 | 85.22% |
| March 31, 2019 | 85.18% |
| December 31, 2018 | 83.01% |
| September 30, 2018 | 73.86% |
| June 30, 2018 | 80.72% |
| March 31, 2018 | 78.53% |
| December 31, 2017 | 74.76% |
| September 30, 2017 | 75.71% |
| June 30, 2017 | 73.83% |
| March 31, 2017 | 61.67% |
| December 31, 2016 | 50.72% |
| September 30, 2016 | 41.70% |
| June 30, 2016 | |
| March 31, 2016 | |
| December 31, 2015 | |
| September 30, 2015 | |
| June 30, 2015 | |
| March 31, 2015 | |
| December 31, 2014 | |
| September 30, 2014 | 0.00% |
| June 30, 2014 | 0.00% |
| March 31, 2014 | 0.00% |
| December 31, 2013 | -23.77% |
| September 30, 2013 | -1.00K% |
Gross Profit Margin Definition
Gross Profit Margin is calculated using Gross Profit/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into gross profit and doing this by keeping cost of goods sold low. An analyst looking at gross profit margin might look for a higher gross profit margin relative to other comparable companies as well as a gross profit margin that is growing.
Gross Profit Margin (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Gross Profit Margin (Quarterly) Benchmarks
| BioMarin Pharmaceutical, Inc. | 72.27% |
| Insmed, Inc. | 83.71% |
| Ligand Pharmaceuticals, Inc. | 82.24% |
| PTC Therapeutics, Inc. | 91.19% |
| Establishment Labs Holdings, Inc. | 70.64% |
Gross Profit Margin (Quarterly) Related Metrics
| Return on Equity | -12.36% |
| Return on Assets | -3.22% |
| Return on Invested Capital | -4.09% |
| Profit Margin (Quarterly) | 0.91% |
| Operating Margin (Quarterly) | 8.61% |
| Return on Net Operating Assets | -5.08% |